Kisspeptin: The Complete Guide

Overview

Kisspeptin is a neuropeptide encoded by the KISS1 gene that plays a central role in the regulation of reproductive hormone release. It acts as the primary upstream signal that triggers the hypothalamic-pituitary-gonadal (HPG) axis — the hormonal cascade responsible for puberty onset, fertility, and sexual maturation. Kisspeptin neurons in the hypothalamus release the peptide, which binds to the KISS1R receptor (also known as GPR54) on gonadotropin-releasing hormone (GnRH) neurons, stimulating GnRH secretion (Seminara et al., 2003).

The discovery of kisspeptin's role in reproduction came from genetic studies showing that individuals with loss-of-function mutations in the KISS1R gene fail to undergo puberty, a condition known as idiopathic hypogonadotropic hypogonadism (IHH). This finding, published independently by two research groups in 2003, established kisspeptin as a critical gatekeeper of the reproductive axis (de Roux et al., 2003; Seminara et al., 2003).

The peptide exists in several isoforms. The full-length precursor, kisspeptin-145, is cleaved into shorter active fragments: kisspeptin-54 (also called metastin), kisspeptin-14, kisspeptin-13, and kisspeptin-10. All active fragments share a common C-terminal decapeptide sequence (the last 10 amino acids) that is sufficient for receptor binding and biological activity. Kisspeptin-54 and kisspeptin-10 are the forms most commonly used in clinical research (Dhillo et al., 2005).

Beyond its role in reproduction, kisspeptin has been investigated for effects on psychosexual arousal, mood, and behavior. Functional neuroimaging studies have demonstrated that kisspeptin administration modulates brain activity in regions associated with sexual arousal and emotional processing, opening a potential therapeutic avenue for disorders of sexual desire (Comninos et al., 2017).

Kisspeptin has no FDA-approved therapeutic indication. It remains an investigational agent with active clinical trials exploring its use in reproductive medicine and psychosexual disorders. It is available through research chemical suppliers but is not available through compounding pharmacies as a prescribed therapeutic.

Quick Facts

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

The Kisspeptin-GnRH-Gonadotropin Axis

Kisspeptin sits at the top of the reproductive hormone cascade. The signaling pathway follows a hierarchical sequence:

1. Kisspeptin neurons in the arcuate nucleus and anteroventral periventricular nucleus (AVPV) of the hypothalamus release kisspeptin in a pulsatile fashion.
2. Kisspeptin binds to KISS1R (GPR54) on the surface of GnRH neurons, activating Gq/11 protein signaling cascades that depolarize the neuron.
3. GnRH is released into the hypophyseal portal system and travels to the anterior pituitary gland.
4. GnRH stimulates gonadotroph cells in the pituitary to secrete LH and FSH into the systemic circulation.
5. LH and FSH act on the gonads — stimulating testosterone production in the testes and estrogen production/ovulation in the ovaries (Seminara et al., 2003).

Pulsatile vs. Continuous Signaling

The pattern of kisspeptin release determines the downstream hormonal response. Pulsatile kisspeptin stimulation maintains robust GnRH pulsatility and sustained gonadotropin secretion. Continuous (non-pulsatile) kisspeptin exposure can initially stimulate but may subsequently desensitize the KISS1R receptor, leading to reduced GnRH output — a phenomenon analogous to the desensitization seen with continuous GnRH agonist administration (Jayasena et al., 2011).

This distinction has clinical implications: pulsatile administration may be required for sustained stimulation of the reproductive axis, while continuous exposure could potentially be used for suppression — though this application remains investigational.

KNDy Neurons

Kisspeptin neurons in the arcuate nucleus co-express two other neuropeptides: neurokinin B (NKB) and dynorphin. These neurons are referred to as KNDy neurons (Kisspeptin/Neurokinin B/Dynorphin). The interplay between these three peptides generates the pulsatile pattern of GnRH release:

• Neurokinin B stimulates kisspeptin release within the KNDy network (autocrine/paracrine stimulation)
• Kisspeptin activates GnRH neurons
• Dynorphin inhibits KNDy neuron activity, terminating the pulse (Navarro et al., 2009)

This pacemaker system is the fundamental generator of GnRH pulses, and disruption of any component can impair reproductive function.

Regulation by Sex Steroids

Kisspeptin neurons are a primary site where sex steroid feedback is integrated into the reproductive axis. Estrogen and testosterone regulate kisspeptin expression differently depending on the hypothalamic region:

• Arcuate nucleus: Sex steroids suppress kisspeptin expression (negative feedback), reducing GnRH pulse frequency when hormone levels are adequate.
• AVPV (in females): Rising estrogen levels stimulate kisspeptin expression (positive feedback), generating the preovulatory LH surge that triggers ovulation (Seminara et al., 2003).

Effects Beyond Reproduction

Kisspeptin and KISS1R are expressed in brain regions beyond the hypothalamus, including the amygdala, hippocampus, and limbic structures. Functional MRI studies in humans have demonstrated that kisspeptin administration modulates activity in brain regions associated with:

• Sexual arousal: Increased activity in regions processing sexual stimuli
• Emotional processing: Enhanced activity in the amygdala and cingulate cortex
• Mood and reward: Modulation of limbic circuit activity (Comninos et al., 2017)

These findings suggest kisspeptin may have direct neuromodulatory effects on sexual desire and emotional behavior, independent of its role in stimulating gonadal hormones.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

Reproductive Endocrinology: Hypogonadism

Kisspeptin has been studied as a potential treatment for hypogonadotropic hypogonadism — a condition where insufficient GnRH signaling leads to low sex hormone production.

• Healthy men: Intravenous kisspeptin-54 administration produced dose-dependent increases in LH, FSH, and testosterone in healthy male volunteers. A bolus of 1 nmol/kg IV produced rapid, significant LH elevation within 30 minutes (Dhillo et al., 2005).
• Healthy women: Kisspeptin-54 stimulated LH secretion in women during the preovulatory phase of the menstrual cycle, with the magnitude of response varying across cycle phases. The greatest LH response occurred during the late follicular phase (Dhillo et al., 2007).
• Hypothalamic amenorrhea: In women with hypothalamic amenorrhea (absent menstruation due to suppressed GnRH), kisspeptin-54 subcutaneous injection restored LH pulsatility and elevated gonadotropin levels, demonstrating that the GnRH neurons remain responsive to kisspeptin even when endogenous kisspeptin signaling is suppressed (Jayasena et al., 2011).
• Men with type 2 diabetes: Kisspeptin infusion increased LH and testosterone levels in men with type 2 diabetes mellitus who had functional hypogonadism, suggesting potential therapeutic application in metabolic-reproductive dysfunction (George et al., 2013).

In Vitro Fertilization (IVF)

One of the most clinically advanced applications of kisspeptin is as a trigger for oocyte maturation in IVF protocols, replacing or supplementing human chorionic gonadotropin (hCG) triggers.

• Oocyte maturation trigger: Subcutaneous kisspeptin-54 (9.6 nmol/kg) was administered as an oocyte maturation trigger in women undergoing IVF. The kisspeptin trigger produced adequate LH surges and resulted in successful oocyte retrieval, fertilization, and live births (Abbara et al., 2015).
• Reduced OHSS risk: A key advantage of kisspeptin as an IVF trigger is the potential to reduce ovarian hyperstimulation syndrome (OHSS) — a serious and sometimes life-threatening complication of IVF. Because kisspeptin produces a more physiological LH surge compared to hCG, the risk of OHSS may be substantially lower. Clinical data from the Imperial College group has supported this hypothesis, with no cases of OHSS reported in kisspeptin-triggered cycles (Abbara et al., 2017).
• Ongoing trials: Larger randomized controlled trials are underway comparing kisspeptin triggers to standard GnRH agonist and hCG triggers in IVF, with OHSS incidence as a primary endpoint.

Psychosexual Function and Brain Imaging

A distinctive area of kisspeptin research involves its effects on sexual arousal, attraction, and emotional processing — studied using functional neuroimaging.

• Male sexual arousal: Kisspeptin-54 infusion in healthy men enhanced brain activity in regions associated with sexual arousal (including the cingulate cortex, thalamus, and putamen) when viewing sexual images, compared to placebo. Kisspeptin also enhanced penile tumescence in response to sexual stimuli (Comninos et al., 2017).
• Negative mood attenuation: Kisspeptin reduced negative mood and enhanced limbic brain activity in response to negative emotional stimuli, suggesting potential antidepressant-like properties in the context of sexual and emotional processing (Comninos et al., 2017).
• Women with hypoactive sexual desire: Preliminary studies have explored kisspeptin administration in women with low sexual desire. Data from the Imperial College London group has shown modulation of brain activity in sexual processing regions, with further trials ongoing (Mills et al., 2020).

Puberty and Development

• Genetic basis of puberty: Loss-of-function mutations in KISS1R cause failure to enter puberty (idiopathic hypogonadotropic hypogonadism), while gain-of-function mutations cause precocious puberty. These genetic findings established kisspeptin as the gatekeeper of pubertal onset (de Roux et al., 2003; Seminara et al., 2003).
• Diagnostic use: Kisspeptin challenge tests have been proposed as a diagnostic tool to differentiate between constitutional delay of puberty and permanent hypogonadotropic hypogonadism in adolescents. The GnRH neuron response to exogenous kisspeptin may indicate the functional status of the reproductive axis (George et al., 2013).

Limitations of the Research

• Small sample sizes: Most human trials have enrolled 10–60 participants. No large-scale Phase 3 trial has been completed.
• Limited research groups: The majority of human clinical data comes from two centers: Imperial College London (Dhillo, Abbara, Comninos) and Massachusetts General Hospital (Seminara, Chan). Independent replication from other groups is limited.
• Short-term studies: Most trials involve single-dose or short-term (days to weeks) administration. Long-term safety and efficacy data is not available.
• Route dependence: Clinical effects have been demonstrated with IV infusion and SC injection; oral bioavailability of kisspeptin is negligible due to rapid enzymatic degradation.
• Tachyphylaxis risk: Continuous kisspeptin exposure may lead to receptor desensitization, limiting chronic use without pulsatile delivery systems.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA Status

Kisspeptin has no FDA-approved indication. It is classified as an investigational agent. Clinical use occurs exclusively within the context of clinical trials or investigator-initiated studies at academic medical centers. It is not available through compounding pharmacies as a prescribed therapeutic.

Investigational Applications

What Kisspeptin Is NOT Used For

• Testosterone replacement: Kisspeptin stimulates endogenous testosterone production via the HPG axis. It is not a direct testosterone replacement and does not bypass the hypothalamic-pituitary pathway.
• Bodybuilding or performance enhancement: While kisspeptin can acutely increase LH and testosterone, the transient nature of the response and tachyphylaxis risk make it unsuitable as a sustained anabolic agent.
• Post-cycle therapy (PCT): Despite interest in the bodybuilding community, kisspeptin has not been studied or validated as a PCT agent after anabolic steroid use.
• Contraception: Although continuous kisspeptin can theoretically suppress the reproductive axis through receptor desensitization, this application has not been developed clinically.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

Published Clinical Trial Protocols

Dosing protocols above are derived from published clinical trials. Key references: Dhillo et al., 2005 · Abbara et al., 2015 · Jayasena et al., 2011 · Abbara et al., 2017

Isoform Considerations

• Kisspeptin-54 has a longer circulating half-life than kisspeptin-10, making it more suitable for SC administration and sustained-effect protocols.
• Kisspeptin-10 has a very short half-life (minutes), requiring IV infusion for sustained effects. It is cleared rapidly by plasma proteases.
• Research chemical suppliers typically offer kisspeptin-10. Clinical trials at academic centers have predominantly used kisspeptin-54.

Route Considerations

• Intravenous: Used in most clinical trial settings. Allows precise dose titration and sustained infusion. Requires clinical environment.
• Subcutaneous: Used in IVF trigger protocols and some sustained-dosing studies. More practical for outpatient use.
• Oral: Not viable. Kisspeptin is rapidly degraded by gastrointestinal and plasma proteases, with negligible oral bioavailability.

Duration and Tachyphylaxis

Continuous kisspeptin administration beyond approximately 12–24 hours has shown evidence of receptor desensitization (tachyphylaxis), with diminishing LH response over time. This limits the use of continuous infusion protocols for sustained HPG axis stimulation. Pulsatile or intermittent dosing strategies may circumvent this limitation, but optimal pulsatile protocols have not been established (Jayasena et al., 2011).

Storage

• Lyophilized powder: Store at -20°C or 2–8°C per supplier specifications. Peptide stability decreases with temperature.
• Reconstituted solution: Refrigerate and use within 24–48 hours in clinical settings. Kisspeptin degrades faster in solution than BPC-157 or similar stable peptides.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What the Clinical Data Shows

Hormonal Response

IVF Outcomes

• Oocyte retrieval: Kisspeptin-54 SC trigger (9.6 nmol/kg) produced adequate LH surges for oocyte maturation. Mature oocyte retrieval rates were comparable to GnRH agonist triggers.
• Fertilization and embryo development: Oocytes retrieved after kisspeptin trigger showed normal fertilization rates and embryo development.
• Live births: Live births have been reported following kisspeptin-triggered IVF cycles (Abbara et al., 2015).
• OHSS: No cases of clinically significant OHSS were reported in kisspeptin-triggered cycles in published data, compared to known OHSS rates of 1–5% with hCG triggers (Abbara et al., 2017).

Psychosexual Outcomes

• Brain activation: fMRI demonstrated significantly enhanced activation in sexual arousal processing regions (cingulate, thalamus, putamen) during kisspeptin infusion vs. placebo.
• Penile tumescence: Kisspeptin enhanced physiological arousal response to sexual stimuli in healthy men.
• Mood: Kisspeptin reduced self-reported negative mood scores and enhanced limbic brain responses to emotional stimuli (Comninos et al., 2017).

Limitations of Reported Results

• Small sample sizes limit generalizability
• Short duration of administration — most studies involve single-dose or multi-day protocols
• Academic center settings with IV infusion capability — not representative of real-world clinical use
• No long-term efficacy data for any application
• Publication bias may overrepresent positive findings

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Reported Side Effects from Clinical Trials

Note: These frequencies are based on small clinical trial populations (typically 10–60 participants). True population-level incidence rates have not been established.

Theoretical Risks and Concerns

• Tachyphylaxis and HPG axis effects: Continuous kisspeptin exposure can desensitize KISS1R, potentially leading to paradoxical suppression of the reproductive axis. The clinical implications of repeated dosing cycles on long-term HPG axis function are unknown.
• Tumor biology: The KISS1 gene was originally identified as a metastasis suppressor gene. Kisspeptin signaling has complex roles in cancer biology — KISS1 expression generally correlates with reduced metastatic potential. However, exogenous kisspeptin administration in the context of cancer has not been studied, and its effects on tumor biology remain theoretical (Seminara et al., 2003).
• Hormonal disruption: Exogenous kisspeptin stimulates the entire HPG axis cascade. Inappropriate use could disrupt normal hormonal cycling, particularly in premenopausal women with intact reproductive function.
• Cardiovascular effects: KISS1R is expressed in cardiovascular tissue. The significance of exogenous kisspeptin on cardiovascular function has not been systematically evaluated.
• Long-term safety: No studies have administered kisspeptin for periods longer than a few weeks. Chronic safety data is entirely absent.

Drug Interactions

No formal drug interaction studies have been conducted. Theoretical interactions include:

• GnRH agonists/antagonists: Kisspeptin acts upstream of GnRH; co-administration with GnRH modulators could produce unpredictable effects on gonadotropin secretion.
• Hormonal contraceptives: Exogenous kisspeptin could interfere with the hormonal suppression underlying contraceptive efficacy.
• Testosterone/estrogen therapy: Exogenous sex steroids provide negative feedback on kisspeptin neurons; combining with exogenous kisspeptin could create competing signals.
• Anti-androgens (e.g., spironolactone, finasteride): Theoretical interaction through altered sex steroid feedback loops.

Contraindications

• Hormone-sensitive cancers — kisspeptin stimulates sex hormone production
• Pregnancy — hormonal disruption could affect pregnancy maintenance
• Children — inappropriate stimulation of the reproductive axis in prepubertal individuals
• Active thromboembolic disease — theoretical concern with acute hormonal changes

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

FDA Status

Kisspeptin has no FDA-approved indication. It is not listed as an approved drug, biologic, or dietary supplement. Clinical use in the United States occurs exclusively under IND applications at academic medical centers conducting approved clinical trials. The FDA has not issued specific guidance or enforcement actions regarding kisspeptin, unlike some other peptides (e.g., BPC-157) that have received Category 2 compounding classifications.

Clinical Trial Landscape

Research Chemical Market

Kisspeptin (typically kisspeptin-10) is available through research chemical suppliers, marketed as "for research purposes only" or "not for human consumption." The same quality and regulatory concerns that apply to other research peptides apply to kisspeptin:

• Not manufactured under cGMP conditions
• Variable purity and potency between suppliers
• No regulatory oversight for human use
• Certificates of analysis may or may not be provided

International Status

Kisspeptin is not approved as a therapeutic agent in any major regulatory jurisdiction (FDA, EMA, MHRA, TGA). Clinical trials are active primarily in the UK (Imperial College London) and the US (Massachusetts General Hospital). Some countries with more permissive research frameworks may allow kisspeptin use in clinical research settings outside of formal IND applications.

WADA Status

Kisspeptin is not specifically named on the WADA Prohibited List. However, it falls under Section S0 (Non-Approved Substances), which prohibits "any pharmacological substance which is not addressed by any of the subsequent sections of the list and with no current approval by any governmental regulatory health authority for human therapeutic use." Athletes subject to anti-doping testing should consider kisspeptin prohibited.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Typical Pricing

Insurance Coverage

Kisspeptin is not covered by any insurance plan. It has no FDA-approved indication and cannot be billed under any drug benefit, medical benefit, or prescription plan. All costs are out-of-pocket. Clinical trial participation is the only pathway to receiving pharmaceutical-grade kisspeptin without direct cost.

Factors Affecting Cost

• Isoform: Kisspeptin-54 is a longer peptide (54 amino acids vs. 10), requiring more complex solid-phase synthesis. It is more expensive per milligram than kisspeptin-10.
• Purity: Higher-purity preparations (>98% HPLC) cost more than lower-purity batches.
• Dosing protocol: IV infusion protocols used in clinical trials require larger total quantities than single-dose SC protocols, though research chemical use typically follows SC protocols at varying doses.
• Supplier reputation: Established peptide suppliers with published COAs and third-party testing charge premium prices compared to unverified sources.

Cost Comparison: Kisspeptin vs. Related Treatments

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Myth: Kisspeptin is a natural testosterone booster.

Answer: Kisspeptin does stimulate endogenous testosterone production — but calling it a "testosterone booster" is misleading. A single IV bolus of kisspeptin-54 produces a transient LH and testosterone increase lasting hours, not days. The effect is acute and dose-dependent. Continuous administration leads to receptor desensitization (tachyphylaxis), which can paradoxically reduce LH output over time (Jayasena et al., 2011). Kisspeptin does not produce sustained testosterone elevation comparable to TRT or hCG protocols. It is not a practical long-term testosterone augmentation strategy with current delivery methods.

Myth: Kisspeptin works like hCG for PCT.

Answer: hCG directly stimulates the Leydig cells in the testes to produce testosterone by mimicking LH. Kisspeptin works upstream — it stimulates GnRH, which stimulates LH, which then stimulates the testes. This indirect mechanism means kisspeptin's effect depends on a functional hypothalamic-pituitary axis. After anabolic steroid use, the HPG axis is often suppressed at multiple levels. Kisspeptin has not been studied as a post-cycle therapy agent, and its efficacy in the context of steroid-induced HPG suppression is unknown. The two agents have fundamentally different mechanisms and are not interchangeable.

Myth: Kisspeptin-10 and kisspeptin-54 are the same thing.

Answer: Both isoforms bind the same receptor (KISS1R) and share the active C-terminal decapeptide sequence. However, they differ significantly in pharmacokinetics. Kisspeptin-54 has a substantially longer circulating half-life, allowing for SC administration and more sustained effects. Kisspeptin-10 is cleared from the bloodstream within minutes, requiring IV infusion for sustained action. The clinical trial data — particularly the IVF and psychosexual data — is predominantly based on kisspeptin-54. Most research chemical suppliers sell kisspeptin-10, which is not pharmacokinetically equivalent (Dhillo et al., 2005).

Myth: Kisspeptin is an aphrodisiac.

Answer: The neuroimaging studies demonstrating that kisspeptin modulates brain activity in sexual arousal regions are methodologically rigorous. However, the magnitude of these effects, their clinical significance, and their translation to meaningful improvements in sexual function in clinical populations remain under investigation. The brain imaging data shows statistically significant changes in neural activation — it does not demonstrate that kisspeptin produces subjective experiences of sexual arousal equivalent to existing pharmaceutical interventions for sexual dysfunction. The research is preliminary and ongoing (Comninos et al., 2017).

Myth: Kisspeptin is safe because it's a natural hormone.

Answer: Kisspeptin is indeed an endogenous neuropeptide. However, "natural" does not equal "safe for exogenous administration." Many endogenous hormones (insulin, cortisol, thyroid hormone) are harmful when administered in inappropriate doses, routes, or durations. Exogenous kisspeptin at supraphysiological doses, non-physiological routes (IV bolus vs. pulsatile hypothalamic release), and without clinical monitoring carries unknown risks. The short-term clinical trial safety profile is favorable, but long-term safety has not been established.

Myth: Kisspeptin can treat infertility on its own.

Answer: Kisspeptin has shown promise as a component of IVF protocols (specifically as an oocyte maturation trigger replacing hCG) and in restoring LH pulsatility in hypothalamic amenorrhea. It is not a standalone infertility treatment. Infertility has numerous causes — tubal factors, endometriosis, sperm quality, uterine abnormalities — most of which would not respond to kisspeptin. Its potential role is as one tool within a comprehensive fertility treatment protocol, not as a replacement for standard fertility evaluation and management.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence:

• Kisspeptin is an endogenous neuropeptide that serves as the primary upstream activator of the hypothalamic-pituitary-gonadal axis. It stimulates GnRH release, which drives LH, FSH, and sex hormone production.
• The evidence base includes human clinical trial data. Unlike many research peptides, kisspeptin has been studied in multiple controlled human trials demonstrating dose-dependent stimulation of reproductive hormones, successful IVF oocyte maturation triggering, and measurable effects on psychosexual brain processing.
• It is not FDA-approved for any indication. All clinical use is investigational, occurring within clinical trials at academic medical centers. It is not available through compounding pharmacies.
• IVF oocyte maturation triggering is the most clinically advanced application, with preliminary data suggesting reduced OHSS risk compared to hCG triggers. Larger randomized trials are ongoing.
• Psychosexual effects are a novel research area. Neuroimaging studies demonstrate measurable brain activation changes, but clinical translation to treatment of sexual desire disorders remains under investigation.
• Tachyphylaxis is a significant limitation. Continuous kisspeptin exposure leads to receptor desensitization, limiting sustained therapeutic use without pulsatile delivery strategies.
• Kisspeptin-54 and kisspeptin-10 are not pharmacokinetically equivalent. Most clinical data is from kisspeptin-54; most research chemical products contain kisspeptin-10.
• Cost ranges from $200–$500/month through research chemical suppliers, with no insurance coverage. Clinical trial participation provides pharmaceutical-grade kisspeptin at no cost.

Who Might Consider Kisspeptin

Based on the current evidence and clinical trial landscape, kisspeptin may be relevant for individuals who:

• Are undergoing IVF and are at elevated risk for OHSS — discussion with a reproductive endocrinologist about kisspeptin trigger trials may be appropriate
• Have hypothalamic amenorrhea or functional hypogonadotropic hypogonadism that has not responded to standard treatment
• Are interested in participating in clinical trials investigating kisspeptin for reproductive or psychosexual applications
• Understand that this is an investigational agent without FDA approval and accept the associated uncertainty

Questions to Ask a Provider

• Are there active kisspeptin clinical trials that I might be eligible for?
• For my specific reproductive condition, how does kisspeptin compare to established treatments (hCG, GnRH, clomiphene)?
• What isoform (kisspeptin-10 vs. -54) is appropriate for my situation, and why?
• What monitoring would be needed during kisspeptin administration?
• What are the realistic expectations for hormonal response given my underlying condition?
• Is pulsatile delivery necessary, and if so, how would that be achieved?

Sources & Further Reading

Foundational Discovery

• de Roux et al. (2003) — "Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54" — PNAS
• Seminara et al. (2003) — "The GPR54 gene as a regulator of puberty" — New England Journal of Medicine

Mechanism of Action

• Seminara et al. (2003) — Kisspeptin-GPR54 signaling in reproductive biology — Endocrinology
• Navarro et al. (2009) — KNDy neurons and GnRH pulse generation — Endocrinology

Human Clinical Trials — Reproductive Endocrinology

• Dhillo et al. (2005) — "Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males" — Journal of Clinical Endocrinology & Metabolism
• Dhillo et al. (2007) — "Kisspeptin-54 stimulates gonadotropin release in women" — Journal of Clinical Endocrinology & Metabolism
• Jayasena et al. (2011) — "Twice-daily SC kisspeptin-54 in hypothalamic amenorrhea" — Journal of Clinical Investigation
• George et al. (2013) — "Kisspeptin in men with type 2 diabetes" — Diabetes Care

IVF Applications

• Abbara et al. (2015) — "Kisspeptin-54 as oocyte maturation trigger in IVF" — Journal of Clinical Endocrinology & Metabolism
• Abbara et al. (2017) — "Kisspeptin trigger and OHSS prevention" — Human Reproduction

Psychosexual Function and Neuroimaging

• Comninos et al. (2017) — "Kisspeptin modulates sexual and emotional brain processing in humans" — Journal of Clinical Investigation
• Mills et al. (2020) — "Kisspeptin and psychosexual processing in women" — Journal of Clinical Endocrinology & Metabolism

Regulatory & Clinical Trials

• ClinicalTrials.gov — Active kisspeptin studies
• WADA: Prohibited List

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.